Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Transcept Pharma Receives $10 Mln Milestone Payment From Purdue - Quick Facts

RELATED NEWS
Trade TSPT now with 

Transcept Pharmaceuticals Inc. (TSPT: Quote) said Wednesday it received a $10 million milestone payment from Purdue Pharma LP in connection with the listing of Intermezzo formulation patents in the FDA Orange Book on December 15, 2011.

The milestone payment was made under the terms of the agreement between Purdue and Transcept for the commercialization of insomnia drug Intermezzo in the US. Purdue plans to launch Intermezzo in the second quarter of 2012 and to invest about $100 million to support marketing during the first year of commercialization.

On November 23, 2011, the FDA approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

Transcept reported cash, cash equivalents and marketable securities of $54.1 million at September 30, 2011, and excludes the $10 million payment received today.

Click here to receive FREE breaking news email alerts for Transcept Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. US President Back Obama on Tuesday announced a new round of sanctions against Russia over Moscow's continued involvement in the ongoing conflict in Ukraine, hours after the European Union decided to expand its own sanctions imposed on Russia over the same issue. "Because we are closely coordinating our actions with Europe, the sanctions we are announcing today will have an even bigger bite. After showing a notable move to the upside in early trading on Tuesday, stocks showed a substantial downturn over the course of the session. Concerns about the impact of new sanctions against Russia weighed on the markets.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.